Windward prices $175M IPO to advance China-licensed lung drugs
BioPharma DiveGwendolyn WuNovember 13, 2026
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.